Posted by Michael Wonder on 19 Mar 2021
Data on AstraZeneca vaccine insufficient for Swiss approval
18 March 2021 - The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the COVID-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
